IMAGE: Novosteo, a Purdue-affiliated startup, is advancing a technology shown to repair bone fractures faster and at greater benefit to a patient. The image above shows fractured femurs at four weeks… view more
Credit: Philip Low/Novosteo
WEST LAFAYETTE, Ind. – A broken bone is challenging for anyone at any age, but for the elderly it can be life threatening. In fact, the Journal of Internal Medicine reported in 2017 that “one in three adults aged 50 and older die within 12 months” from fracture-related complications following a bone-breaking fall. Medicare alone paid $31 billion in hip fracture treatment in 2015.
A $1.7 million National Science Foundation SBIR Phase I/II grant to a Purdue University-affiliated startup will help fast-track to human trials a novel injectable-targeted drug that shows great promise in accelerating and improving the healing of broken or compromised bones. The drug is unique in that it concentrates at the fracture site following systemic administration while reducing exposure to the rest of the body.
The grant will support the drugs’ efficacy testing and preparation for Phase 1 clinical human trials.
Novosteo Inc., the startup developing the drug, was co-founded by father/son team Philip S. Low, the Ralph C. Corley
Article originally posted at